The system, dubbed the “molecular truck”, offers an alternative to traditional methods of 5-aminosalicylic acid delivery to the colon. “This drug has the potential to be a major advancement in the treatment of infants and children with ulcerative colitis, who have difficulty taking available medications,” said pediatric gastroenterologist Fayez Ghishan, MD.
Rather than in large pill form, the drug could be administered orally in the form of a suspension in highly concentrated doses targeted directly at the GI tract. The delivery system would also offer mitigation of side effects.
The molecular truck was developed by:
• Dr. Ghishan, head of pediatrics and director of the UA Steele Children’s Research Center, College of Medicine – Tucson
• Eugene Mash Jr., PhD, professor of chemistry and biochemistry
• Pawel Kiela, DVM, PhD, associate professor of pediatrics and Steele Center researcher
More articles on gastroenterology:
11 gastroenterologists serving as ASC medical directors
GI physician leader to know: Dr. Edgar Achkar of Cleveland Clinic
5 gastroenterologists making headlines this week
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.